IP Therapy Proves Non-Superior to IV/Bevacizumab Combination in Ovarian Cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, April 27, 2016

IP Therapy Proves Non-Superior to IV/Bevacizumab Combination in Ovarian Cancer



targeted oncology item

.... “All arms had substantial toxicity,” Walker said. “Neurotoxicity was equally high in all arms. We reserve judgment on recommendations until survival is available. IP cisplatin probably shouldn’t be combined with bevacizumab because it causes severe hypertension.”

An analysis of patient-reported outcomes (PROs)—quality of life, neuropathy, nausea, fatigue, and abdominal discomfort—showed consistently lower scores among patients in the cisplatin arm.

PRO scores did not differ appreciably between the two carboplatin arms, with the exception of slower improvement in abdominal discomfort in patients treated with IP carboplatin.


References
  1. Walker JL, Brady MF, DiSilvestro PA, et al. A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma NCI-supplied agent(s): bevacizumab (NSC #704865, IND #7921) NCT01167712 a GOG/NRG trial (GOG 252). Presented at: 2016 SGO Annual Meeting. March 19-22, 2016. San Diego, CA. Late-breaking abstract.
  2. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.

0 comments :

Post a Comment

Your comments?